Matches in SemOpenAlex for { <https://semopenalex.org/work/W1570753218> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W1570753218 endingPage "5851s" @default.
- W1570753218 startingPage "5847s" @default.
- W1570753218 abstract "Evidence is presented for two different breast epithelial antigens that some epitopes have greater tumor specificity and are more effective targets for radioimmunotherapy than others. The two antigens, which are major components of the human milk fat globule membrane, are breast mucin and a M(r) 46,000 glycoprotein (BA46). Of five monoclonal antibodies (Mc5, Mc1, BrE-1, BrE-2, and BrE-3) against breast mucin, all recognize overlapping amino acid epitopes on the tandem repeat domain. However, each have unique and different tissue and tumor specificities and unique epitope structures on the fully glycosylated breast mucin. In preclinical studies, radioimmunoconjugates of all five monoclonal antibodies inhibit growth of transplantable breast tumors in immunodeficient mice. In human clinical trials, radioiodinated Mc5 was very poor in localizing breast tumor metastases. On the other hand, 111In-labeled BrE-3 imaged almost 90% of breast tumors and showed promise in radioimmunotherapy when labeled with 90Y. The failure of Mc5 in clinical trials may be partly attributed to the high levels of its epitope on circulating mucin compared to the epitope of BrE-3. The Mc5 binding affinity increased significantly with glycosylation, while the BrE-3 epitope was masked by glycosylation. The BA46 glycoprotein is a breast tumor-associated membrane antigen containing an NH2-terminal, epidermal growth factor-like domain into which a cell adhesion sequence (RGD) is inserted and a COOH-terminal domain with homology to the phospholipid binding C1/C2 domain of coagulation factors V and VIII. It promotes cell attachment in an RGD-dependent manner. Monoclonal antibody Mc8, which binds to the C2-like domain, is only moderately effective in experimental radioimmunotherapy, while Mc3, which binds an epitope in the EGF-like RGD domain, was highly effective in destroying breast tumors in nude mice. With 90Y-labeled Mc3, 6 of 7 mice are cured of the tumors. These results indicate that by selecting appropriate monoclonal antibodies, a normal antigen can be used as a target for radioimmunotherapy." @default.
- W1570753218 created "2016-06-24" @default.
- W1570753218 creator A5020981900 @default.
- W1570753218 creator A5031342395 @default.
- W1570753218 creator A5046199922 @default.
- W1570753218 creator A5090172616 @default.
- W1570753218 date "1995-12-01" @default.
- W1570753218 modified "2023-09-23" @default.
- W1570753218 title "Selection of tumor-specific epitopes on target antigens for radioimmunotherapy of breast cancer." @default.
- W1570753218 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7493358" @default.
- W1570753218 hasPublicationYear "1995" @default.
- W1570753218 type Work @default.
- W1570753218 sameAs 1570753218 @default.
- W1570753218 citedByCount "13" @default.
- W1570753218 countsByYear W15707532182019 @default.
- W1570753218 countsByYear W15707532182023 @default.
- W1570753218 crossrefType "journal-article" @default.
- W1570753218 hasAuthorship W1570753218A5020981900 @default.
- W1570753218 hasAuthorship W1570753218A5031342395 @default.
- W1570753218 hasAuthorship W1570753218A5046199922 @default.
- W1570753218 hasAuthorship W1570753218A5090172616 @default.
- W1570753218 hasConcept C108625454 @default.
- W1570753218 hasConcept C147483822 @default.
- W1570753218 hasConcept C153911025 @default.
- W1570753218 hasConcept C159654299 @default.
- W1570753218 hasConcept C179264091 @default.
- W1570753218 hasConcept C185592680 @default.
- W1570753218 hasConcept C195616568 @default.
- W1570753218 hasConcept C203014093 @default.
- W1570753218 hasConcept C2776146153 @default.
- W1570753218 hasConcept C2777313579 @default.
- W1570753218 hasConcept C2777421810 @default.
- W1570753218 hasConcept C502942594 @default.
- W1570753218 hasConcept C542903549 @default.
- W1570753218 hasConcept C55493867 @default.
- W1570753218 hasConcept C86803240 @default.
- W1570753218 hasConceptScore W1570753218C108625454 @default.
- W1570753218 hasConceptScore W1570753218C147483822 @default.
- W1570753218 hasConceptScore W1570753218C153911025 @default.
- W1570753218 hasConceptScore W1570753218C159654299 @default.
- W1570753218 hasConceptScore W1570753218C179264091 @default.
- W1570753218 hasConceptScore W1570753218C185592680 @default.
- W1570753218 hasConceptScore W1570753218C195616568 @default.
- W1570753218 hasConceptScore W1570753218C203014093 @default.
- W1570753218 hasConceptScore W1570753218C2776146153 @default.
- W1570753218 hasConceptScore W1570753218C2777313579 @default.
- W1570753218 hasConceptScore W1570753218C2777421810 @default.
- W1570753218 hasConceptScore W1570753218C502942594 @default.
- W1570753218 hasConceptScore W1570753218C542903549 @default.
- W1570753218 hasConceptScore W1570753218C55493867 @default.
- W1570753218 hasConceptScore W1570753218C86803240 @default.
- W1570753218 hasIssue "23 Suppl" @default.
- W1570753218 hasLocation W15707532181 @default.
- W1570753218 hasOpenAccess W1570753218 @default.
- W1570753218 hasPrimaryLocation W15707532181 @default.
- W1570753218 hasRelatedWork W1574353069 @default.
- W1570753218 hasRelatedWork W1956510278 @default.
- W1570753218 hasRelatedWork W1974813327 @default.
- W1570753218 hasRelatedWork W1999215232 @default.
- W1570753218 hasRelatedWork W2074545760 @default.
- W1570753218 hasRelatedWork W2148497582 @default.
- W1570753218 hasRelatedWork W2413353068 @default.
- W1570753218 hasRelatedWork W2484853651 @default.
- W1570753218 hasRelatedWork W2804368738 @default.
- W1570753218 hasRelatedWork W254627720 @default.
- W1570753218 hasVolume "55" @default.
- W1570753218 isParatext "false" @default.
- W1570753218 isRetracted "false" @default.
- W1570753218 magId "1570753218" @default.
- W1570753218 workType "article" @default.